ArchiMed Acquires Majority Stake in NAMSA

NAMSA (ARCHIMED) Acquires Clinlogix

August 2, 2021

Healthcare Services

Toledo-based NAMSA, a portfolio company of healthcare-focused private equity firm ARCHIMED, has acquired Clinlogix, a Lower Gwynedd, Pennsylvania-based contract research organization (CRO) focused on medical device clinical trials. The deal expands NAMSA's clinical trial capacity by roughly 25%, deepens therapeutic expertise in neurology, oncology, urology and nephrology, and strengthens global trial capabilities with Clinlogix facilities in Japan, Germany and Colombia.

NAMSA Acquires Syntactx

January 5, 2021

Healthcare Services

NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.

NAMSA Acquires American Preclinical Services (APS)

March 2, 2021

Medical Devices

Toledo-based NAMSA, a medical-device-focused contract research organization owned by ARCHIMED's MED Platform I, has acquired Minneapolis-based American Preclinical Services (APS). The add-on expands NAMSA's lab, surgical instrumentation and imaging capabilities and increases its footprint in Minnesota; debt financing for the deal was provided by funds managed by Ares Management Corporation.

NAMSA Acquires SUAZIO

March 27, 2023

Healthcare Services

ARCHIMED-funded NAMSA has acquired SUAZIO, a Belgium-headquartered, data-driven life sciences and MedTech marketing and research consultancy. The add-on expands NAMSA's strategic consulting, market research and commercialization capabilities across medical devices and IVD markets; SUAZIO's founder reinvested proceeds and will continue to lead its consultancy services.

ARCHIMED (MED Platform I) Acquires Majority Stake in CARSO

December 16, 2021

Healthcare Services

Transatlantic healthcare private equity firm ARCHIMED, via its MED Platform I fund and in partnership with CAPZA Expansion and Siparex, has acquired a majority stake in Lyon-based CARSO, a leader in purity and analytical testing for pharma, healthcare, environmental and food sectors. The deal (debt provided by Tikehau Capital and several banks) will support CARSO's internationalization and service-range expansion as the group aims to more than double current annual revenues (above €200 million).

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.